• Je něco špatně v tomto záznamu ?

Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG): An International Interobserver Study

B. Xu, AL. Barbieri, JA. Bishop, SI. Chiosea, S. Dogan, S. Di Palma, WC. Faquin, R. Ghossein, M. Hyrcza, VY. Jo, JS. Lewis, JR. Lozada, M. Michal, FG. Pareja, B. Perez-Ordonez, ML. Prasad, B. Purgina, JS. Reis-Filho, T. Scognamiglio, APM....

. 2020 ; 44 (4) : 545-552. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025092

Grantová podpora
P01 CA240239 NCI NIH HHS - United States
P30 CA008748 NCI NIH HHS - United States

Polymorphous adenocarcinoma (PAC) shows histologic diversity with streaming and targetoid features whereas cribriform adenocarcinoma of salivary gland (CASG) demonstrates predominantly cribriform and solid patterns with glomeruloid structures and optically clear nuclei. Opinions diverge on whether CASG represents a separate entity or a variant of PAC. We aimed to assess the level of agreement among 25 expert Head and Neck pathologists in classifying these tumors. Digital slides of 48 cases were reviewed and classified as: PAC, CASG, tumors with ≥50% of papillary architecture (PAP), and tumors with indeterminate features (IND). The consensus diagnoses were correlated with a previously reported molecular alteration. The consensus diagnoses were PAC in 18/48, CASG in16/48, PAP in 3/48, and IND in 11/48. There was a fair interobserver agreement in classifying the tumors (κ=0.370). The full consensus was achieved in 3 (6%) cases, all of which were classified as PAC. A moderate agreement was reached for PAC (κ=0.504) and PAP (κ=0.561), and a fair agreement was reached for CASG (κ=0.390). IND had only slight diagnostic concordance (κ=0.091). PAC predominantly harbored PRKD1 hotspot mutation, whereas CASG was associated with fusion involving PRKD1, PRKD2, or PRKD3. However, such molecular events were not exclusive as 7% of PAC had fusion and 13% of CASG had mutation. In conclusion, a fair to moderate interobserver agreement can be achieved in classifying PAC and CASG. However, a subset (23%) showed indeterminate features and was difficult to place along the morphologic spectrum of PAC/CASG among expert pathologists. This may explain the controversy in classifying these tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025092
003      
CZ-PrNML
005      
20201222155046.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAS.0000000000001431 $2 doi
035    __
$a (PubMed)31917707
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Xu, Bin $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
245    10
$a Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG): An International Interobserver Study / $c B. Xu, AL. Barbieri, JA. Bishop, SI. Chiosea, S. Dogan, S. Di Palma, WC. Faquin, R. Ghossein, M. Hyrcza, VY. Jo, JS. Lewis, JR. Lozada, M. Michal, FG. Pareja, B. Perez-Ordonez, ML. Prasad, B. Purgina, JS. Reis-Filho, T. Scognamiglio, APM. Sebastiao, RR. Seethala, A. Skálová, SM. Smith, MS. Tekkeşin, LDR. Thompson, JK. Wasseman, BM. Wenig, I. Weinreb, N. Katabi,
520    9_
$a Polymorphous adenocarcinoma (PAC) shows histologic diversity with streaming and targetoid features whereas cribriform adenocarcinoma of salivary gland (CASG) demonstrates predominantly cribriform and solid patterns with glomeruloid structures and optically clear nuclei. Opinions diverge on whether CASG represents a separate entity or a variant of PAC. We aimed to assess the level of agreement among 25 expert Head and Neck pathologists in classifying these tumors. Digital slides of 48 cases were reviewed and classified as: PAC, CASG, tumors with ≥50% of papillary architecture (PAP), and tumors with indeterminate features (IND). The consensus diagnoses were correlated with a previously reported molecular alteration. The consensus diagnoses were PAC in 18/48, CASG in16/48, PAP in 3/48, and IND in 11/48. There was a fair interobserver agreement in classifying the tumors (κ=0.370). The full consensus was achieved in 3 (6%) cases, all of which were classified as PAC. A moderate agreement was reached for PAC (κ=0.504) and PAP (κ=0.561), and a fair agreement was reached for CASG (κ=0.390). IND had only slight diagnostic concordance (κ=0.091). PAC predominantly harbored PRKD1 hotspot mutation, whereas CASG was associated with fusion involving PRKD1, PRKD2, or PRKD3. However, such molecular events were not exclusive as 7% of PAC had fusion and 13% of CASG had mutation. In conclusion, a fair to moderate interobserver agreement can be achieved in classifying PAC and CASG. However, a subset (23%) showed indeterminate features and was difficult to place along the morphologic spectrum of PAC/CASG among expert pathologists. This may explain the controversy in classifying these tumors.
650    _2
$a adenokarcinom $x klasifikace $x genetika $x patologie $7 D000230
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a biopsie $7 D001706
650    _2
$a mutační analýza DNA $7 D004252
650    _2
$a fúze genů $7 D050939
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a mutace $7 D009154
650    _2
$a odchylka pozorovatele $7 D015588
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a nádory slinných žláz $x klasifikace $x genetika $x patologie $7 D012468
651    _2
$a Kanada $7 D002170
651    _2
$a Evropa $7 D005060
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Barbieri, Andrea L $u Department of Pathology, Yale University School of Medicine, New Haven, CT.
700    1_
$a Bishop, Justin A $u Department of Pathology, UT Southwestern Medical Center, Dallas, TX.
700    1_
$a Chiosea, Simon I $u Department of Pathology, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, PA.
700    1_
$a Dogan, Snjezana $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
700    1_
$a Di Palma, Silvana $u Department of Histopathology, The Royal Surrey County Hospital, Guildford, UK.
700    1_
$a Faquin, William C $u Department of Pathology, Massachusetts General Hospital.
700    1_
$a Ghossein, Ronald $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
700    1_
$a Hyrcza, Martin $u Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Centre, Calgary, AB.
700    1_
$a Jo, Vickie Y $u Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
700    1_
$a Lewis, James S $u Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.
700    1_
$a Lozada, John R $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
700    1_
$a Michal, Michal $u Department of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.
700    1_
$a Pareja, Fresia G $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
700    1_
$a Perez-Ordonez, Bayardo $u Department of Pathology, University Health Network, University of Toronto, Toronto.
700    1_
$a Prasad, Manju L $u Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
700    1_
$a Purgina, Bibianna $u Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
700    1_
$a Reis-Filho, Jorge S $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
700    1_
$a Scognamiglio, Theresa $u Department of Pathology, Cornell University, New York, NY.
700    1_
$a Sebastiao, Ana P M $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
700    1_
$a Seethala, Raja R $u Department of Pathology, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, PA.
700    1_
$a Skálová, Alena $u Department of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.
700    1_
$a Smith, Stephen M $u Department of Pathology, University Health Network, University of Toronto, Toronto.
700    1_
$a Tekkeşin, Merva S $u Department of Tumour Pathology, Institute of Oncology, University of Istanbul, Istanbul, Turkey.
700    1_
$a Thompson, Lester D R $u Department of Pathology, Southern California Permanente Medical Group, CA.
700    1_
$a Wasseman, Jason K $u Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
700    1_
$a Wenig, Bruce M $u Department of Pathology, Moffitt Cancer Center, University of South Florida, Tampa, FL.
700    1_
$a Weinreb, Ilan $u Department of Pathology, University Health Network, University of Toronto, Toronto.
700    1_
$a Katabi, Nora $u Department of Pathology, Memorial Sloan-Kettering Cancer Center.
773    0_
$w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 44, č. 4 (2020), s. 545-552
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31917707 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155042 $b ABA008
999    __
$a ok $b bmc $g 1599237 $s 1115778
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 44 $c 4 $d 545-552 $e - $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
GRA    __
$a P01 CA240239 $p NCI NIH HHS $2 United States
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace